Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
COMBAT HBV Feasibility Trial
NCT05705427Phase 4Completed
- Sponsor
- University of North Carolina at Chapel Hill
- Start
- Aug 2023
- Primary completion
- Nov 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial in hepatitis B (HBV) comparing Tenofovir disoproxil fumarate (TDF) arm with Placebo arm (2 arms). Primary endpoints: Number of Pregnant Women With Adverse Effects Related to Study Medications at 12 months, Number of Infants with Adverse Effects Related to Study Medications and 8 more. Started Aug 2023; status: completed.
02
Drugs
tenofovir disoproxil fumarate
03
Conditions
hepatitis B (HBV)
Beyond the preview
Go deeper on NCT05705427.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05705427.